Get startedLog in
    Picture of Basilea Pharmaceutica AG, Allschwil logo

    BSLN — Basilea Pharmaceutica AG, Allschwil News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Basilea Receives Additional USD 6 Million Funding From Carb-X

    Picture of Basilea Pharmaceutica AG, Allschwil logoBasilea Pharmaceutica AG, Allschwil
    09/04/2026 06:19
    April 9 (Reuters) - Basilea Pharmaceutica AG Allschwil BSLN.S:

RECEIVES ADDITIONAL USD 6 MILLION FUNDING FROM CARB-X

FUNDING TO SUPPORT FIRST-IN-HUMAN PHASE 1 STUDY OF BAL2420

BASILEA PHARMACEUTICA - FIRST SUBJECT DOSED IN PHASE 1 STUDY OF BAL2420 IN MARCH 2026

Source text: ID:nGNX2t06gM

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Basilea Pharmaceutica AG, Allschwil

    See all news